AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00678145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study NCT00678145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study NCT00678145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study NCT00678145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study NCT03388463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 80 mg continues infusion
Study NCT03388463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Omeprazole 40 mg single daily dose.
Study NCT00114790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: boronophenylalanine-based BNCT
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study NCT01022398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol/placebo
Description: 10,000 IU by mouth weekly for 6 months
Study NCT01022398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol/placebo
Description: 10,000 IU by mouth weekly for 6 months
Study NCT00624455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
Study NCT00624455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02452372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: givosiran (ALN-AS1)
Description: Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
Study NCT02452372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study NCT00292500 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Automated distal anastomotic device
Description: CABG
Study NCT01977235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01977235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT01977235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01977235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02658422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Montelukast
Description: Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Study NCT02658422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
Study NCT03750851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
Study NCT03750851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPPACPF
Description: In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
Study NCT03750851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
Study NCT03750851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LaserCPPACPF
Description: In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
Study NCT04147468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
Study NCT04147468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Strength Training
Description: For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
Study NCT04009941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 4.5mg per cycle, 24 hours after chemotherapy
Study NCT00734669 — intervention group
Intervention type: DRUG
Intervention: Glibenclamide
Description: Taking a single dose of 3.5 mg glibenclamide
Study NCT02762513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Study NCT04278885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: 300mg Lanadelumab s.c. administration every 2 weeks
Study NCT04304131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Earlytect Colon Cancer
Description: A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
Study NCT04304131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Earlytect Colon Cancer
Description: A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
Study NCT02574533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
Study NCT02574533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
Study NCT00135603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate potassium
Description: 1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
Study NCT00135603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: ablation of the appendix by laparotomy or laparoscopy
Study NCT01817738 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CV9104
Description: Intradermal injection of CV9104
Study NCT01817738 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of placebo
Study NCT01961479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT for patients with PMS
Description: Internet-based cognitive-behavioural self-help treatment
Study NCT01961479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: During the waiting period, participants receive no treatment.
Study NCT04290702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional analgesia for labor
Description: three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
Study NCT03932071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study NCT04295070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
Study NCT04295070 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline (0.9%) administered via dropper
Study NCT02393391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroelectrics STARSTIM
Study NCT02393391 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuroelectrics STARSTIM
Study NCT03390413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot
Description: Renal cancer treated with robotic surgery
Study NCT03390413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Renal cancer treated with cryoablation
Study NCT04693052 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
Study NCT00870337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT00188630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Study NCT00188630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose solution
Study NCT04307342 — intervention group
Intervention type: PROCEDURE
Intervention: MIPO with Extra-articular Distal Humeral Anatomical Plate
Description: MIPO with Extra-articular Distal Humeral Anatomical Plate
Study NCT03848299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Single Arm
Description: All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants.
Study NCT03646448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
Study NCT05233657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX11502MA
Description: Oral capsule
Study NCT00969982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
Study NCT00969982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol+placebo
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
Study NCT05233657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT02201160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega 3
Description: Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
Study NCT02201160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
Study NCT04162210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study NCT02617901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Left hand DXA
Description: All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order.
Study NCT01417013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Lubricant Eye Drops
Study NCT01417013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: Lubricant eye drops
Study NCT01131013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.
Study NCT04162210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pom/dex (Pomalidomide plus low dose Dexamethasone)
Description: Pomalidomide and Dexamethasone will be administered.
Study NCT02651428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrolin
Description: Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
Study NCT02651428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
Study NCT02911766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.2% Mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
Study NCT02911766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
Study NCT02911766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.06% mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
Study NCT04737473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiod Free Anesthesia
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
Study NCT04737473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opiod Free Anesthesia
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
Study NCT01291901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP2
Description: NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
Study NCT01291901 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
Study NCT01193400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study NCT01193400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT03015805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency Management (CM) utilizes behavior modification \& cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks.
Study NCT01131013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT01131013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT03015805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Probation as Usual
Description: Standard services that a young person would receive while under probation supervision in the state of Oregon.
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient advice, encouragement, and education
Description: Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient advice, encouragement, and education
Description: Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation
Description: High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
Study NCT02619500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilizations
Description: Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC9204-0530
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration.